These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15468527)

  • 21. Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate.
    Tachibana M; Sato C; Otsuki H; Sattabongkot J; Kaneko O; Torii M; Tsuboi T
    Vaccine; 2012 Feb; 30(10):1807-12. PubMed ID: 22245309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global genetic diversity of the Plasmodium vivax transmission-blocking vaccine candidate Pvs48/45.
    Vallejo AF; Martinez NL; Tobon A; Alger J; Lacerda MV; Kajava AV; Arévalo-Herrera M; Herrera S
    Malar J; 2016 Apr; 15():202. PubMed ID: 27067024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of Pvs28 in sporozoite development in Anopheles sinensis and its longevity in BALB/c mice.
    Kim TS; Kim HH; Moon SU; Lee SS; Shin EH; Oh CM; Kang YJ; Kim DK; Sohn Y; Kim H; Lee HW
    Exp Parasitol; 2011 Feb; 127(2):346-50. PubMed ID: 20801117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Worldwide sequence conservation of transmission-blocking vaccine candidate Pvs230 in Plasmodium vivax.
    Doi M; Tanabe K; Tachibana S; Hamai M; Tachibana M; Mita T; Yagi M; Zeyrek FY; Ferreira MU; Ohmae H; Kaneko A; Randrianarivelojosia M; Sattabongkot J; Cao YM; Horii T; Torii M; Tsuboi T
    Vaccine; 2011 Jun; 29(26):4308-15. PubMed ID: 21514344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Ex Vivo Assay to Evaluate Functional Effectiveness of Plasmodium vivax Transmission-Blocking Vaccine Using Pvs25 Transgenic Plasmodium berghei.
    Cao Y; Hayashi CTH; Kumar N
    J Infect Dis; 2024 Jun; 229(6):1894-1903. PubMed ID: 38408353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein.
    Arévalo-Herrera M; Solarte Y; Yasnot MF; Castellanos A; Rincón A; Saul A; Mu J; Long C; Miller L; Herrera S
    Am J Trop Med Hyg; 2005 Nov; 73(5 Suppl):32-7. PubMed ID: 16291764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
    Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A
    Malar J; 2007 Aug; 6():107. PubMed ID: 17686163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission.
    Blagborough AM; Yoshida S; Sattabongkot J; Tsuboi T; Sinden RE
    Vaccine; 2010 Aug; 28(37):6014-20. PubMed ID: 20637303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploration of genetic diversity of Plasmodium vivax circumsporozoite protein (Pvcsp) and Plasmodium vivax sexual stage antigen (Pvs25) among North Indian isolates.
    Kaur H; Sehgal R; Kumar A; Sehgal A; Bharti PK; Bansal D; Mohapatra PK; Mahanta J; Sultan AA
    Malar J; 2019 Sep; 18(1):308. PubMed ID: 31492135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine.
    Miyata T; Harakuni T; Sugawa H; Sattabongkot J; Kato A; Tachibana M; Torii M; Tsuboi T; Arakawa T
    Vaccine; 2011 Mar; 29(15):2720-6. PubMed ID: 21315699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low genetic polymorphism of merozoite surface proteins 7 and 10 in Colombian Plasmodium vivax isolates.
    Garzón-Ospina D; Romero-Murillo L; Tobón LF; Patarroyo MA
    Infect Genet Evol; 2011 Mar; 11(2):528-31. PubMed ID: 21182986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Restricted genetic heterogeneity of the Plasmodium vivax transmission-blocking vaccine (TBV) candidate Pvs48/45 in a low transmission setting: Implications for the Plasmodium vivax malaria vaccine development.
    Asali S; Raz A; Turki H; Mafakher L; Razmjou E; Solaymani-Mohammadi S
    Infect Genet Evol; 2021 Apr; 89():104710. PubMed ID: 33421653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Highly efficient protein expression of Plasmodium vivax surface antigen, Pvs25, by silkworm and its biochemical analysis.
    Miyata T; Minamihata K; Kurihara K; Kamizuru Y; Gotanda M; Obayashi M; Kitagawa T; Sato K; Kimura M; Oyama K; Ikeda Y; Tamaki Y; Lee JM; Sakao K; Hamanaka D; Kusakabe T; Tachibana M; Ibrahim HR
    Protein Expr Purif; 2022 Aug; 195-196():106096. PubMed ID: 35460871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization.
    Miyata T; Harakuni T; Tsuboi T; Sattabongkot J; Kohama H; Tachibana M; Matsuzaki G; Torii M; Arakawa T
    Infect Immun; 2010 Sep; 78(9):3773-82. PubMed ID: 20584978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasmodium vivax: C-terminal diversity in the blood stage SERA genes from Indian field isolates.
    Rahul CN; Shiva Krishna K; Meera Bai N; Kumar V; Phadke S; Rajesh V
    Exp Parasitol; 2013 May; 134(1):82-91. PubMed ID: 23485360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasmodium vivax malaria vaccine development.
    Arévalo-Herrera M; Herrera S
    Mol Immunol; 2001 Dec; 38(6):443-55. PubMed ID: 11741694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes.
    Arakawa T; Tsuboi T; Kishimoto A; Sattabongkot J; Suwanabun N; Rungruang T; Matsumoto Y; Tsuji N; Hisaeda H; Stowers A; Shimabukuro I; Sato Y; Torii M
    Vaccine; 2003 Jul; 21(23):3143-8. PubMed ID: 12804841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of transmission-blocking activity of candidate Pvs25 vaccine using gametocytes from chimpanzees.
    Collins WE; Barnwell JW; Sullivan JS; Nace D; Williams T; Bounngaseng A; Roberts J; Strobert E; McClure H; Saul A; Long CA
    Am J Trop Med Hyg; 2006 Feb; 74(2):215-21. PubMed ID: 16474073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative study on worldwide genetic diversity and population structure analysis of Plasmodium vivax thrombospondin-related adhesive protein (PvTRAP) and its implications for the vivax vaccine design.
    Nazeri S; Mehrizi AA; Djadid ND; Zakeri S
    Infect Genet Evol; 2015 Dec; 36():410-423. PubMed ID: 26477931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasmodium vivax: genetic diversity of the apical membrane antigen-1 (AMA-1) in isolates from India.
    Rajesh V; Elamaran M; Vidya S; Gowrishankar M; Kochar D; Das A
    Exp Parasitol; 2007 Jul; 116(3):252-6. PubMed ID: 17336299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.